GSK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	1.58M
Average Volume	3.56M
Market Cap	80.66B
EPS	$0 ( 2024-01-31 )
Next earnings date	( $0.950 ) 2024-04-24
Last Dividend	$0.340 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	13.34
ATR14	$0.0140 (0.04%)

Volume Correlation

Long: 0.44 (neutral)

Short: 0.82 (strong)

Signal:(59.071) Same movement expected

GlaxoSmithKline PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations
YSAC	-0.891

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlaxoSmithKline PLC Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

-0.73
( moderate negative )

0.30
( neutral )

0.71
( moderate )

GlaxoSmithKline PLC Financials

Annual	2023
Revenue:	$30.33B
Gross Profit:	$21.25B (70.07 %)
EPS:	$1.220

Q4	2023
Revenue:	$8.05B
Gross Profit:	$5.71B (70.96 %)
EPS:	$0.0863

Q3	2023
Revenue:	$8.15B
Gross Profit:	$5.88B (72.11 %)
EPS:	$0.360

Q2	2023
Revenue:	$7.18B
Gross Profit:	$5.25B (73.08 %)
EPS:	$0.400

Financial Reports:

No articles found.

GlaxoSmithKline PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.391 (N/A)	$0.317 (N/A)	$0.340 (N/A)	$0.348 (N/A)	$0.361 (N/A)	$0.340 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Sustainability Score: 9.66 - good (96.56%) | Divividend Growth Potential Score: 6.26 - Stable (25.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0420	1987-05-15
Last Dividend	$0.340	2023-11-16
Next Dividend	$0	N/A
Payout Date	2024-01-11
Next Payout Date	N/A
# dividends	120	--
Total Paid Out	$57.37	--
Avg. Dividend % Per Year	2.89%	--
Score	6.04	--
Div. Sustainability Score	9.66
Div.Growth Potential Score	6.26
Div. Directional Score	7.96	--

Next Divdend (Est)
(2024-06-03)

$0.335 Estimate 38.07 %

Dividend Stability

0.76 Good

Dividend Score

6.04

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.184	2.39%
1988	$0.135	1.42%
1989	$0.319	3.31%
1990	$0.468	3.63%
1991	$0.567	3.45%
1992	$0.861	2.70%
1993	$0.363	1.52%
1994	$1.027	4.86%
1995	$1.159	5.55%
1996	$1.164	4.14%
1997	$1.218	3.88%
1998	$1.148	2.39%
1999	$1.134	1.60%
2000	$2.03	3.65%
2001	$0.854	1.53%
2002	$1.889	3.79%
2003	$1.368	3.55%
2004	$1.604	3.43%
2005	$1.527	3.22%
2006	$1.738	3.41%
2007	$2.06	3.83%
2008	$2.14	4.27%
2009	$1.855	5.02%
2010	$1.998	4.65%
2011	$2.21	5.62%
2012	$2.48	5.35%
2013	$2.41	5.46%
2014	$2.65	5.02%
2015	$2.45	5.78%
2016	$2.77	6.85%
2017	$2.06	5.31%
2018	$2.16	5.85%
2019	$2.05	5.40%
2020	$2.06	4.39%
2021	$2.21	5.85%
2022	$1.680	3.85%
2023	$1.389	3.94%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.387	1.500	6.82	10.00	[0.1 - 1]
payoutRatioTTM	0.456	-1.000	5.44	-5.44	[0 - 1]
currentRatioTTM	0.885	0.800	-0.575	-0.460	[1 - 3]
quickRatioTTM	0.597	0.800	-1.192	-0.954	[0.8 - 2.5]
cashRatioTTM	0.139	1.500	-0.337	-0.505	[0.2 - 2]
debtRatioTTM	0.288	-1.500	5.21	-7.81	[0 - 0.6]
interestCoverageTTM	9.12	1.000	7.73	7.73	[3 - 30]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.035	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	1.271	-1.500	4.92	-7.37	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.330	1.330	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.24	7.24	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.386	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.514	0.800	9.91	7.93	[0.5 - 2]
Total Score				9.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	26.69	1.000	7.40	0	[1 - 100]
returnOnEquityTTM	0.387	2.50	7.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.035	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	4.49	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.456	1.500	5.44	-5.44	[0 - 1]
pegRatioTTM	0.492	1.500	-0.0539	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.216	1.000	7.11	0	[0.1 - 0.5]
Total Score				6.26

GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Realtime updates for GlaxoSmithKline PLC [GSK]

Upcoming Earnings Alert

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)